Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neuromodulation Augmented Cognitive Remediation to Improve Executive Dysfunction in Fetal Alcohol Spectrum Disorder (FASD)

NCT03361293 is registered in ClinicalTrials.gov with University of Minnesota as lead sponsor.

NCT NCT03361293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03361293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neuromodulation Augmented Cognitive Remediation to Improve Executive Dysfunction in Fetal Alcohol Spectrum Disorder (FASD)
Lead sponsor
University of Minnesota
Phase
Not applicable
Overall status
Completed
Start date
November 20, 2017
Completion date
January 30, 2020
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fetal alcohol spectrum disorders